The Ohio State University Comprehensive Cancer Center (OSUCCC) is currently in its 39th year as an NCI designated CCC, having received an ?exceptional? overall merit descriptor following its last review in 2010 and now requesting continued federal support for the next five years. Dr. Caligiuri continues in his twelfth year as the OSUCCC Director and his seventh year as CEO of OSU's freestanding James Cancer Hospital. The OSUCCC mission remains to reduce cancer morbidity and mortality through continued basic, translational and clinical research. The 222 OSUCCC full, associate or introductory members are currently served by 14 shared resources and are distributed among our five Research Programs which are: Cancer Control, Translational Therapeutics (formerly Experimental Therapeutics), Molecular Biology and Cancer Genetics, Molecular Carcinogenesis and Chemoprevention and a new Leukemia Research Program. The OSUCCC addresses the public health needs of the catchment area (the state of Ohio) through research and outreach, from etiology through prevention, treatment and survivorship among the major cancers afflicting its population ? lung, colorectal, breast, and prostate. This is done by addressing risky behaviors (tobacco use, obesity, HPV infection and lack of screening) and the higher incidence of and mortality from cancers among the following groups: the poor; the underserved populations of Ohio Appalachia; and inner city African-Americans. Since the last CCSG competitive renewal, the OSUCCC has shown significant growth as demonstrated by: 1) the recruitment of 145 faculty focused in basic, translational and clinical cancer research and cancer medicine, 58 of whom have become OSUCCC members; 2) the addition of 1,326,300 nsf of new space under the full control of the OSUCCC Director at a cost of $1.2 billion and including a new 1.1 million nsf James Cancer Hospital; 3) obtaining a $100M HRSA grant award to construct a state-of-the-art Radiation Oncology Center in the new James Cancer Hospital; 4) a 51% increase in patient accrual to interventional therapeutic trials reflective of robust growth in solid tumor research; 5) the addition of 2 new shared resources at an institutional investment of over $2 million; 6) strong team science as demonstrated by a 12.5% increase in NCI programmatic grant funding (as a fraction of our nearly $45 million in total direct NCI funding); 7) an increase in the mean percent NCI funding proportion to total CCSG funding for our five research programs from 51% to 61%, reflective of increased cancer focus; 8) enhanced collaborative research as demonstrated by a publication portfolio in which 64% of manuscripts are multi-institutional and 84.4% are collaborative (i.e., inter-, intra-programmatic or multi-institutional); and 9) preclinical and clinical development of two agents, one of which changed the landscape in cancer and both of which were subsequently FDA approved. With new recruits and resources in place and building on the momentum of our research work to date, the OSUCCC is poised in these coming five years to take significant steps toward achieving our mission and ultimately our vision of a cancer-free world.

Public Health Relevance

OVERALL NARRATIVE The Ohio State University Comprehensive Cancer Center (OSUCCC) is a matrix cancer center that integrates and leverages all of the resources of the University to achieve its broad vision of creating a cancer free world. The OSUCCC addresses the public health needs of the catchment area (the state of Ohio) through research and outreach. Research conducted within the five OSUCCC Programs focuses on ways to reduce the higher rates of lung, breast, CRC and prostate cancer as well as the higher prevalence of risky behaviors such as lack of screening, obesity, high tobacco use, and lack of HPV vaccine. Outreach efforts through the OSUCCC address the needs of underserved populations - lower education; poor; inner city African American; rural and urban Hispanic; Appalachian; rural; Amish; and Somali - by providing targeted, culturally appropriate education activities, free cancer screenings, patient navigation, community networking, environmental scans, community gardening, and addressing policy issues (eg, tobacco-free campus).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016058-41S1
Application #
9378861
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-12
Project End
2020-11-30
Budget Start
2016-12-01
Budget End
2017-11-30
Support Year
41
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Pan, Pan; Oshima, Kiyoko; Huang, Yi-Wen et al. (2018) Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. Int J Cancer 143:886-896

Showing the most recent 10 out of 2602 publications